Page 63 - Read Online

Stenina-Adognravi et al. Vessel Plus 2018;2:30 I http://dx.doi.org/10.20517/2574-1209.2018.40 Page 13 of 14

131. Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, et al. Metronomic low-dose chemotherapy boosts CD95-dependent anti-
angiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res 2005;11:6678-
85.
132. Henkin J, Volpert OV. Therapies using anti-angiogenic peptide mimetics of thrombospondin-1. Expert Opin Ther Targets 2011;15:1369-
86.
133. Haviv F, Bradley MF, Kalvin DM, Schneider AJ, Davidson DJ, et al. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and
tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem 2005;48:2838-46.
134. Huang H, Campbell SC, Bedford DF, Nelius T, Veliceasa D, et al. Peroxisome proliferator-activated receptor gamma ligands improve
the antitumor efficacy of thrombospondin peptide ABT510. Mol Cancer Res 2004;2:541-50.
135. Punekar S, Zak S, Kalter VG, Dobransky L, Punekar I, et al. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogen-
esis and inflammation in a murine model of inflammatory bowel disease. Pathobiology 2008;75:9-21.
136. Rogers NM, Sharifi-Sanjani M, Csányi G, Pagano PJ, Isenberg JS. Thrombospondin-1 and CD47 regulation of cardiac, pulmonary and
vascular responses in health and disease. Matrix Biol 2014;37:92-101.
137. Jeanne A, Sick E, Devy J, Floquet N, Belloy N, et al. Identification of TAX2 peptide as a new unpredicted anti-cancer agent. Oncotarget
2015;6:17981-8000.
138. Jeanne A, Martiny L, Dedieu S. Thrombospondin-targeting TAX2 peptide impairs tumor growth in preclinical mouse models of child-
hood neuroblastoma. Pediatr Res 2017;81:480-8.
139. Jeanne A, Boulagnon-Rombi C, Devy J, Théret L, Fichel C, et al. Matricellular TSP-1 as a target of interest for impeding melanoma
spreading: towards a therapeutic use for TAX2 peptide. Clin Exp Metastasis 2016;33:637-49.
140. Li G, Wu H, Cui L, Gao Y, Chen L, et al. CD47-retargeted oncolytic adenovirus armed with melanoma differentiation-associated gene-
7/interleukin-24 suppresses in vivo leukemia cell growth. Oncotarget 2015;6:43496-507.
141. Maxhimer JB, Soto-Pantoja DR, Ridnour LA, Shih HB, Degraff WG, et al. Radioprotection in normal tissue and delayed tumor growth
by blockade of CD47 signaling. Sci Transl Med 2009; doi: 10.1126/scitranslmed.3000139.
142. Soto-Pantoja DR, Miller TW, Pendrak ML, DeGraff WG, Sullivan C, et al. CD47 deficiency confers cell and tissue radioprotection by
activation of autophagy. Autophagy 2012;8:1628-42.
143. Soto-Pantoja DR, Terabe M, Ghosh A, Ridnour LA, DeGraff WG, et al. CD47 in the tumor microenvironment limits cooperation be-
tween antitumor T-cell immunity and radiotherapy. Cancer Res 2014;74:6771-83.
144. Isenberg JS, Maxhimer JB, Hyodo F, Pendrak ML, Ridnour LA, et al. Thrombospondin-1 and CD47 limit cell and tissue survival of ra-
diation injury. Am J Pathol 2008;173:1100-12.
145. Jeanne A, Schneider C, Martiny L, Dedieu S. Original insights on thrombospondin-1-related antireceptor strategies in cancer. Front
Pharmacol 2015;6:252.
146. Krukovets I, Legerski M, Sul P, Stenina-Adognravi O. Inhibition of hyperglycemia-induced angiogenesis and breast cancer tumor
growth by systemic injection of microRNA-467 antagonist. FASEB J 2015;29:3726-36.
147. Moura R, Tjwa M, Vandervoort P, Van Kerckhoven S, Holvoet P, et al. Thrombospondin-1 deficiency accelerates atherosclerotic plaque
maturation in ApoE-/- mice. Circ Res 2008;103:1181-9.
148. Xing T, Wang Y, Ding WJ, Li YL, Hu XD, et al. Thrombospondin-1 production regulates the inflammatory cytokine secretion in THP-1
cells through NF-κB signaling pathway. Inflammation 2017;40:1606-21.
149. Stein EV, Miller TW, Ivins-O’Keefe K, Kaur S, Roberts DD. Secreted thrombospondin-1 regulates macrophage interleukin-1β
production and activation through CD47. Sci Rep 2016;6:19684.
150. Zhao Y, Xion, Z, Lechner EJ, Klenotic PA, Hamburg BJ, et al. Thrombospondin-1 triggers macrophage IL-10 production and promotes
resolution of experimental lung injury. Mucosal Immunol 2013;7:440-8.
151. Csányi G, Feck DM, Ghoshal P, Singla B, Lin H, et al. CD47 and Nox1 mediate dynamic fluid-phase macropinocytosis of native LDL.
Antioxid Redox Signal 2017;26:886-901.
152. Liu Z, Morgan S, Ren J, Wang Q, Annis DS, et al. Thrombospondin-1 (TSP1) contributes to the development of vascular inflammation
by regulating monocytic cell motility in mouse models of abdominal aortic aneurysm. Circ Res 2015;117:129-41.
153. Li Y, Qi X, Tong X, Wang S. Thrombospondin 1 activates the macrophage toll-like receptor 4 pathway. Cell Mol Immunol 2013;10:506-
12.
154. Peter MR, Jerkic M, Sotov V, Douda DN, Ardelean DS, et al. Impaired resolution of inflammation in the endoglin heterozygous mouse
model of chronic colitis. Mediators Inflamm 2014; doi: 10.1155/2014/767185.
155. Wu L, Derynck R. Essential role of TGF-beta signaling in glucose-induced cell hypertrophy. Dev Cell 2009;17:35-48.
156. Wheeler SE, Lee NY. Emerging roles of transforming growth factor β signaling in diabetic retinopathy. J Cell Physiol 2017;232:486-9.
157. Melzer C, Hass R, von der Ohe J, Lehnert H, Ungefroren H. The role of TGF-β and its crosstalk with RAC1/RAC1b signaling in breast
and pancreas carcinoma. Cell Commun Signal 2017;15:19.
158. Wintrob ZA, Hammel JP, Nimako GK, Gaile DP, Forrest A, et al. Dataset on growth factor levels and insulin use in patients with diabe-
tes mellitus and incident breast cancer. Data Brief 2017;11:183-91.
159. Park SY, Kim MJ, Park SA, Kim JS, Min KN, et al. Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesen-
chymal transition and breast cancer stem-like cells. Oncotarget 2015;6:37526-43.
160. Kim D, Lee AS, Jung YJ, Yang KH, Lee S, et al. Tamoxifen ameliorates renal tubulointerstitial fibrosis by modulation of estrogen recep-
tor α-mediated transforming growth factor-β1/Smad signaling pathway. Nephrol Dial Transplant 2014;29:2043-53.
161. Park CY, Min KN, Son JY, Park SY, Nam JS, et al. An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung me-